keyword
MENU ▼
Read by QxMD icon Read
search

Anastrozole

keyword
https://www.readbyqxmd.com/read/29755596/phytochemicals-current-strategies-for-treating-breast-cancer
#1
REVIEW
Bridg'ette B Israel, Syreeta L Tilghman, Kitani Parker-Lemieux, Florastina Payton-Stewart
Females with early-stage metastatic, estrogen-dependent breast cancer are generally treated with surgery, radiation and chemotherapy, or with more targeted approaches such as aromatase inhibitors (anastrozole or letrozole) or anti-estrogens (tamoxifen). Despite widespread successful usage of these agents for the treatment of breast cancer, resistance, tumor relapse and metastasis remain the principal causes of mortality for patients with breast cancer. While numerous groups have made major contributions toward an improved understanding of resistance mechanisms, the currently insufficient grasp of the most critical pathways involved in resistance is evident in the inability to adequately treat and drastically improve patient outcomes in females with hormone-refractory breast cancer, including triple negative breast cancer...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29720397/increased-long-qt-and-torsade-de-pointes-reporting-on-tamoxifen-compared-with-aromatase-inhibitors
#2
Virginie Grouthier, Benedicte Lebrun-Vignes, Andrew M Glazer, Philippe Touraine, Christian Funck-Brentano, Antoine Pariente, Carine Courtillot, Anne Bachelot, Dan M Roden, Javid J Moslehi, Joe-Elie Salem
OBJECTIVE: A prolonged QTc (LQT) is a surrogate for the risk of torsade de pointes (TdP). QTc interval duration is influenced by sex hormones: oestradiol prolongs and testosterone shortens QTc. Drugs used in the treatment of breast cancer have divergent effects on hormonal status. METHODS: We performed a disproportionality analysis using the European database of suspected adverse drug reaction (ADR) reports to evaluate the reporting OR (ROR χ2 ) of LQT, TdP and ventricular arrhythmias associated with selective oestrogen receptor modulators (SERMs: tamoxifen and toremifene) as opposed to aromatase inhibitors (AIs: anastrozole, exemestane and letrozole)...
May 2, 2018: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29684698/biophysical-characterization-of-aptenodytes-forsteri-cytochrome-p450-aromatase
#3
Francisco Zarate-Perez, Jesús B Velázquez-Fernández, Gareth K Jennings, Lisa S Shock, Charles E Lyons, John C Hackett
Cytochrome P450 19 (CYP19, aromatase) catalyzes the conversion of androgens to estrogens in a sequence of three reactions that each depend on NADPH and O2 . Aromatase is a phylogenetically-ancient enzyme and its breadth of expression in other species has highlighted distinct physiological functions. In songbirds, estrogen production is required for programming the neural circuits controlling song and in the determination of sex in fish and reptiles. This work describes the expression, purification, and biophysical characterization of Aptenodytes forsteri (Emperor penguin, af) aromatase...
April 7, 2018: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/29683499/the-role-of-androgens-on-periodontal-repair-in-female-rats
#4
João Paulo Steffens, Luis Carlos Leal Santana, Jonleno Coutinho Paiva Pitombo, Daniel Olivio Ribeiro, Maria Carolina Costa Albaricci, Stephanie von Stein Cubas Warnavin, Alpdogan Kantarci, Luis Carlos Spolidorio
BACKGROUND: Testosterone replacement enhances cognitive function and musculoskeletal health in postmenopausal women. However, the biological role of testosterone on inflammation and bone metabolism in females is not well understood. Our objective was to measure the impact of androgens and their receptors on periodontal tissues during periodontal repair in female rats. METHODS: Seventy female Holtzman rats were divided into seven groups (n = 10/group): negative control; repair control; androgen receptor antagonist (flutamide, 50 mg/kg, every other day); estrogen receptor antagonist (fulvestrant, 1...
April 2018: Journal of Periodontology
https://www.readbyqxmd.com/read/29668491/erythematous-maculopapular-eruption-induced-by-anastrozole-the-first-case
#5
Emanuele Cozzani, Ilaria Trave, Martina Burlando, Aurora Parodi
No abstract text is available yet for this article.
April 9, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29659187/bioequivalence-of-oral-formulations-of-anastrozole-in-healthy-chinese-male-volunteers-a-randomized-single-dose-two-period-two-sequence-crossover-study
#6
Jiangying Chen, Jialang Zhuang, Jingguo Wu, Xiaoyan Chen, Xueding Wang, Lihui Huang, Guixiong Zeng, Jie Chen, Xiaoxing Liao, Xiao Chen, Zhongfu Ma, Guoping Zhong, Min Huang, Dafang Zhong, Xianglan Zhao
Anastrozole is currently used as first-line treatment in locally advanced or metastatic breast cancer. A generic anastrozole tablet was developed to offer an alternative to the marketed tablet formulation. The aim of the current study was to evaluate the bioequivalence between the test and reference formulations of anastrozole in a single-dose, 2-period, 2-sequence crossover study with a 14-day washout interval. A total of 20 healthy male Chinese volunteers were enrolled and completed the study, after oral administration of a single dose of 1...
April 16, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29610032/personalized-prevention-in-high-risk-individuals-managing-hormones-and-beyond
#7
D Gareth Evans, Sacha J Howell, Anthony Howell
Increasing numbers of women are being identified at 'high-risk' of breast cancer, defined by The National Institute of Health and Care Excellence (NICE) as a 10-year risk of ≥8%. Classically women have been so identified through family history based risk algorithms or genetic testing of high-risk genes. Recent research has shown that assessment of mammographic density and single nucleotide polymorphisms (SNPs), when combined with established risk factors, trebles the number of women reaching the high risk threshold...
March 30, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29609880/progression-free-survival-with-first-line-endocrine-based-therapies-among-postmenopausal-women-with-hr-her2-metastatic-breast-cancer-a-network-meta-analysis
#8
REVIEW
Rajeev Ayyagari, Derek Tang, Oscar Patterson-Lomba, Zhou Zhou, Jipan Xie, David Chandiwana, Anand A Dalal, Polly Ann Niravath
PURPOSE: The comparative efficacy of endocrine-based therapies (ETs) for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) is not well characterized. This network meta-analysis (NMA) synthesized available evidence on progression-free survival (PFS) with first-line ETs for postmenopausal HR+/HER2- mBC. METHODS: A systematic literature review identified randomized controlled trials of first-line ETs...
March 30, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29607425/investigation-of-genotoxicity-risk-and-dna-repair-capacity-in-breast-cancer-patients-using-anastrozole
#9
Tugce Yesil Devecioglu, Fatih Aydogan, Gulden Zehra Omurtag, Nuran Senel Bese, Semra Sardas
OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs...
2018: Northern Clinics of Istanbul
https://www.readbyqxmd.com/read/29574365/health-related-quality-of-life-from-the-falcon-phase-iii-randomised-trial-of-fulvestrant-500-mg-versus-anastrozole-for-hormone-receptor-positive-advanced-breast-cancer
#10
John F R Robertson, Kwok-Leung Cheung, Shinzaburo Noguchi, Zhimin Shao, Arnold Degboe, Jasmine Lichfield, Jackie Thirlwell, Mehdi Fazal, Matthew J Ellis
BACKGROUND: The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC). Furthermore, overall health-related quality of life (HRQoL) was maintained and comparable for fulvestrant and anastrozole. Here, we present additional analyses of patient-reported HRQoL outcomes from FALCON...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29567078/beneficial-role-of-biochanin-a-on-cutaneous-and-renal-tissues-of-ovariectomized-rats-treated-with-anastrozole
#11
Azza A A Galal, Amany Abdel-Rahman Mohamed, Safaa I Khater, Mohamed M M Metwally
AIMS: This study was designed to assess the beneficial role of biochanin A (BCA) in the protection of the cutaneous and renal tissues of ovariectomized rats, even in those treated with anastrozole (ANA). MATERIALS AND METHODS: For this purpose, 60 adult female Wistar rats were allocated into 6 equal groups. Rats in group I (sham) underwent a sham operation and received distilled water orally. In groups II and III, OVX rats received either distilled water orally or DMSO intraperitoneally, respectively...
March 19, 2018: Life Sciences
https://www.readbyqxmd.com/read/29554282/effects-of-celecoxib-and-low-dose-aspirin-on-outcomes-in-adjuvant-aromatase-inhibitor-treated-patients-cctg-ma-27
#12
Kathrin Strasser-Weippl, Michaela J Higgins, Judith-Anne W Chapman, James N Ingle, George W Sledge, George T Budd, Matthew J Ellis, Kathleen I Pritchard, Mark J Clemons, Tanja Badovinac-Crnjevic, Lei Han, Karen A Gelmon, Manuela Rabaglio, Catherine Elliott, Lois E Shepherd, Paul E Goss
Background: Celecoxib and low-dose aspirin might decrease risk of breast cancer recurrence. Methods: In the Canadian Cancer Trials Group MA.27, postmenopausal hormone receptor-positive breast cancer patients were randomly assigned (2 × 2) to adjuvant exemestane or anastrozole, and celecoxib or placebo. Low-dose aspirin of 81 mg or less was a stratification factor. Due to concerns about cardiac toxicity, celecoxib use was stopped in December 2004, while stratification by aspirin use was removed through protocol amendment...
March 15, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29546343/ovarian-function-recovery-during-anastrozole-in-breast-cancer-patients-with-chemotherapy-induced-ovarian-function-failure
#13
Irene E G van Hellemond, Ingeborg J H Vriens, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Caroline M Seynaeve, Maurice J C van der Sangen, Judith R Kroep, Hiltje de Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Jos J E M Kitzen, Maaike de Boer, Wïlfred K de Roos, Sabine C Linn, Alexander L T Imholz, Vivianne C G Tjan-Heijnen
Background: Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with chemotherapy-induced ovarian function failure. The current analysis reports on endocrine data of patients with chemotherapy-induced ovarian function failure who were included in the phase III DATA study assessing different durations of adjuvant anastrozole after tamoxifen. Methods: We identified all patients with chemotherapy-induced ovarian function failure...
December 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29536789/in-case-of-anastrozole-related-hallucinations-can-switching-to-letrozole-be-a-treatment-option-a-case-report-and-literature-review
#14
Yakup Bozkaya, Gökmen Umut Erdem, Nebi Serkan Demirci
Arthralgia, myalgia, paresthesia, reduced bone mineral density, vasomotor side effects including hot flashes and night sweats, genitourinary symptoms including decreased libido, vaginal dryness and dyspareunia are common side effects of aromatase inhibitors. Unlike the common side effects, the information on neurological side effects like hallucination of aromatase inhibitor was limited in literature cases. Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29485645/correlation-of-serum-estradiol-and-duration-of-anastrazole-therapy-with-treatment-related-adverse-effects-among-postmenopausal-breast-cancer-women-a-cross-sectional-study
#15
M B Abubakar, S H Gan
Although anastrozole (Anas) plays a key role in the management of endocrine sensitive post-menopausal (PM) breast cancer (BC), there is much variability in its efficacy and tolerability. Anas-associated musculoskeletal symptoms (MS) and other adverse reactions, such as hot flashes (HF) and vaginal dryness/dyspareunia (VDD), are common and can affect the quality of life of BC patients, even sometimes leading to treatment withdrawal. The aim of this study was to determine the clinical and demographic factors associated with these adverse events...
December 30, 2017: Nigerian Journal of Physiological Sciences: Official Publication of the Physiological Society of Nigeria
https://www.readbyqxmd.com/read/29483990/segmental-erythema-multiforme-like-drug-eruption-by-aromatase-inhibitor-anastrozole-first-case-report-and-another-example-of-an-immunocompromised-district
#16
Uwe Wollina, Jacqueline Schönlebe, Birgit Heinig, Georgi Tchernev, Katlein França, Torello Lotti
Anastrozole is a non-selective aromatase inhibitor for adjuvant breast cancer therapy in postmenopausal women. Cutaneous adverse events have been reported. We observed a 64-year-old female patient with a medical history of locally advanced breast cancer of her right breast that was treated with radiotherapy and adjuvant drug therapy with anastrozole. She developed a segmental bullous eruption limited to the cancer-affected breast. Cessation of the aromatase inhibitor and systemic therapy with prednisolone cleared the lesions completely...
January 25, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29482983/adjuvant-anastrozole-versus-exemestane-versus-letrozole-upfront-or-after-2-years-of-tamoxifen-in-endocrine-sensitive-breast-cancer-fata-gim3-a-randomised-phase-3-trial
#17
Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Alessio Aligi Cogoni, Francesco Cognetti, Stefania Gori, Jennifer Foglietta, Antonio Frassoldati, Domenico Amoroso, Lucio Laudadio, Luca Moscetti, Filippo Montemurro, Claudio Verusio, Antonio Bernardo, Vito Lorusso, Adriano Gravina, Gabriella Moretti, Rossella Lauria, Antonella Lai, Carmela Mocerino, Sergio Rizzo, Francesco Nuzzo, Paolo Carlini, Francesco Perrone
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. METHODS: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer...
April 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29470723/cyclin-dependent-kinase-4-6-inhibitors-as-first-line-treatment-for-post-menopausal-metastatic-hormone-receptor-positive-breast-cancer-patients-a-systematic-review-and-meta-analysis-of-phase-iii-randomized-clinical-trials
#18
Allan Ramos-Esquivel, Hellen Hernández-Steller, Marie-France Savard, Denis Ulises Landaverde
BACKGROUND: To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with advanced hormone receptor-positive breast cancer. MATERIALS AND METHODS: Phase III randomized clinical trials (RCT) were identified after a systematic review of electronic databases. A random-effect model was used to determine the pooled hazard ratio (HR) for progression-free survival (PFS) using the inverse-variance method...
February 22, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29468454/randomized-phase-ii-study-of-anastrozole-plus-tegafur-uracil-as-neoadjuvant-therapy-for-er-positive-breast-cancer-in-postmenopausal-japanese-women-neo-acet-bc
#19
Takahiro Nakayama, Yasuaki Sagara, Tsutomu Takashima, Nobuki Matsunami, Norikazu Masuda, Yasuo Miyoshi, Tetsuya Taguchi, Toyokazu Aono, Toshikazu Ito, Tatsuo Kagimura, Shinzaburo Noguchi
PURPOSE: This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer. METHODS: Postmenopausal Japanese women with ER-positive, HER2-negative, T2,N0-1,M0 breast cancer seen at tertiary hospitals were eligible for this open-label, randomized, multicenter study. Patients were randomized 1:1 by minimization to orally receive either anastrozole (1 mg once daily) plus UFT (tegafur/uracil combination in 1:4 molar ratio; 270 mg/m2 /day in two divided doses) or anastrozole (as above) alone for 24 weeks...
April 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29455298/patient-reported-predictors-of-early-treatment-discontinuation-treatment-related-symptoms-and-health-related-quality-of-life-among-postmenopausal-women-with-primary-breast-cancer-randomized-to-anastrozole-or-exemestane-on-ncic-clinical-trials-group-cctg-ma
#20
Lynne I Wagner, Fengmin Zhao, Paul E Goss, Judith-Anne W Chapman, Lois E Shepherd, Timothy J Whelan, Bassam I Mattar, Jose A Bufill, William C Schultz, Irving E LaFrancis, Gauri G Nagargoje, Radhakrishna Vemuri, Daniel A Nikcevich, George W Sledge, David Cella
PURPOSE: Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane. METHODS: MA...
February 17, 2018: Breast Cancer Research and Treatment
keyword
keyword
11983
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"